Table 1 Overview of Patients included in the study
Case-note review | Interviews | |
|---|---|---|
Total number of Patients | 62 | 13 |
Male | 45 | 10 |
Female | 17 | 3 |
Median age | 66 (range 48–81) | |
Disease | ||
Lung | 51 | 11 |
Prostate | 4 | 0 |
Bladder | 4 | 1 |
Head and Neck | 2 | 0 |
Squamous cell cancer of skin | 1 | 1 |
Pembrolizumab | 55 (11 trial) | 10 |
Pembrolizumab +Docetaxel | 2 (1 trial) | |
Nivolumab | 5 (5 trial) | |
Atezolimumab | 5 | 3 |
Median number of cycles | 3 (range 1–32) | 9 (range 2–30) |